L-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol bitartrate

We are L-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol bitartrate CAS:69815-49-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Norepinephrine Bitartrate
4-(2-Amino-1-hydroxyethyl)benzene-1,2-diol 2,3-dihydroxysuccinate (1:1)
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, 2,3-dihydroxybutanedioate (1:1) (salt)
EINECS 211-268-5
4-(2-amino-1-hydroxyethyl)benzene-1,2-diol 2,3-dihydroxybutanedioate (1:1)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol 2,3-dihydroxysuccinate (1:1)
Molecular Formula: C12H17NO9
Molecular Weight: 319.265
Appearance and traits: white or almost white crystals
Melting point: 100-106ºC
Storage conditions: 2-8ºC
Applications: Adrenergic receptor hormone medicine.

Items of Analysis Standard of Analysis Test Results
Appearance White or almost white Crystalline Powder Conform
Identification A: imfrared absorption
B: Feric chloride TS
C: 0.1N iodin
Specific Rotation [a]D20 -10.0o~ -12.0o -11.4o
Water 4.5%-5.8% 5.1%
Limit of Adrenalone A310nm ≤0.2 0.017
Residue On Ignition ≤0.1% 0.02%
Resldula solvents
≤5000pmm 290ppm
Assay(Died) 97.0-102.0% 99.6%
Conclusion Conforms to Factory Standard

 L-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol bitartrate

Related News: Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.2-bromo-1-methoxy-1-methylcyclohexane The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.2,5,7-Trimethyl-benzoxazol-ethoiodid f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national.Methyl (1α,2β,5α)-2-methyl-4-methylene-3,7-dioxobicyclo(3.3.0)octane-2-carboxylate The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.

Related Products
Product Name
p-Anisaldehyde View Details
2-Chloro-5-nitroanisole View Details
Methyl N-cyanoethanimideate View Details
2-Fluoro-4-bromo-5-chlorotoluene Cas:201849-17-4 manufacturer 2-Chloro-4-toluidine Cas:615-65-6 manufacturer 3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluoro-1-octanol Cas:647-42-7 manufacturer Carbomer Cas:9007-20-9 manufacturer 4,4′-bis(chloromethyl)-1,1′-biphenyl Cas:1667-10-3 manufacturer